Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"tyrosine kinase inhibitor (TKI)"”.
-
An optical proteomic profile of the HER2 family in breast tumours and the effect of exposure to tyrosine kinase inhibitors
… of the effects of HER2-targeted therapy with the tyrosine kinase inhibitor (TKI) lapatinib, in vitro, and elucidation of the ensuing conformational changes may help understand the molecular activity of lapatinib and elucidate mechanisms of resistance. Clinical translation of this knowledge may …
-
Flourescent Biosensor-Based, Cdc42 Activity Imaging For Understanding the Regulation of Epidermal Growth Receptor (EGFR) Signalling in Head and Neck Cancer
… in Squamous Carcinoma Cell Lines after EGFR tyrosine kinase inhibitor (TKI) treatment, using the FRET biosensor Raichu-Cdc42. I have demonstrated that conversely, Raichu-Cdc42, and consequently endogenous Cdc42 activity increases significantly following EGFR TKI treatment. Further …
-
The role of receptor tyrosine kinase signalling in HER-2-positive cells and trastuzumab (Herceptin) resistance in breast cancer
… cancer. Signalling through alternative receptor tyrosine kinases, such as insulin-like growth factor I receptor (IGF-IR), has been implicated in resistance to Tmab. The main aim of this study was to investigate mechanisms of resistance and in particular the role of IGF-IR in resistance to Tmab. …
-
Development and application of novel analytical methods for molecularly targeted cancer therapeutics
… were developed for the quantification of 1) tyrosine kinase inhibitor anti-cancer drugs to examine the interaction of these agents with drug resistance mechanisms, and 2) the multiple myeloma drug thalidomide as a pilot study to identify potential correlations between serum drug levels and …
-
GENERATION OF SYNTHETIC ANTIBODIES AS POTENTIAL THERAPEUTICS TO BLOCK IL3–MEDIATED INNATE IMATINIB RESISTANCE IN CHRONIC MEYLOID LEUKEMIA
… resistance in chronic myeloid leukemia (CML). Tyrosine kinase inhibitor (TKI), imatinib, is the standard therapy for CML. Although many patients respond to the conventional TKI chemotherapy, the majority relapse upon withdrawal of treatment (Ross et al., 2013) implicating the inability of TKIs …
-
Defining CP-CML patient subsets associated with poor imatinib uptake and response.
The introduction of tyrosine kinase inhibitor (TKI) therapy, specifically imatinib, has dramatically improved the treatment outcome for the majority of chronic phase chronic myeloid leukaemia (CP-CML) patients. Although most patients will achieve excellent clinical (haematological, cytogenetic and …
-
Expression and function of drug transporters in primitive CML cells
… line of treatment is imatinib mesylate (IM), a tyrosine kinase inhibitor (TKI) that competes with ATP to block ABL kinase activity, which in turn prevents tyrosine phosphorylation of downstream molecules and selectively induces apoptosis of BCR-ABL cells. However, despite excellent cytogenetic …
-
Studying the Transcriptional and Epigenetic Perturbations of Haematopathologies Expressing NPM1-ALK
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in the development of the gut and nervous system, initially cloned from cases of T-cell lymphoma. ALK has been frequently implicated in diverse cancers through oncogenic translocations, mutations, chromosomal inversion, or amplification …